Skip to main content

Table 3 Study parameters values at baseline, day 45 and day 90 in treatment groups

From: Single-blind, placebo controlled randomised clinical study of chitosan for body weight reduction

Study parameters Chitosan (mean ± SD) [range] Placebo (mean ± SD) [range]
Day 0 (N = 64) Day 45 (N = 59) Day 90 (N = 56) Day 0 (N = 32) Day 45 (N = 31) Day 90 (N = 30)
Body mass Index (Kg/m2) 30.93 ± 2.69 [26.49 – 35.19] 30.20 ± 2.90* [25.32 – 35.08] 29.71 ± 3.07* [24.88 – 35.64] 30.91 ± 2.72
[26.23 – 34.95]
30.95 ± 2.62 [26.29 – 34.95] 30.83 ± 2.64 [26.36 – 35.09]
Body fat (%) 37.88 ± 6.86 [25.20 – 49.50] 37.36 ± 7.03* [25.00 – 50.30] 36.65 ± 7.25* [24.30 – 49.40] 37.96 ± 7.83 [23.70 – 49.30] 38.02 ± 8.00 [23.70 – 49.30] 38.07 ± 8.09 [23.50 – 49.10]
Visceral fat (%) 10.80 ± 3.52
[4 – 20]
10.47 ± 3.3*
[4 – 20]
9.71 ± 3.33*
[4 – 20]
10.53 ± 2.97
[4 – 17]
10.55 ± 2.75
[5 – 17]
10.43 ± 2.87
[5 – 17]
Muscle mass (Kg) 47.52 ± 9.62 [32.20 – 68.30] 46.74 ± 9.50* [32.00 – 64.50] 46.84 ± 9.57* [31.70 – 64.20] 46.95 ± 10.79 [34.70 – 81.10] 47.04 ± 11.17 [35.20 – 83.80] 47.50 ± 11.01 [35.20 – 83.00]
Upper abdominal circumference (cm) 97.70 ± 7.96 [80.00 – 114.0] 96.61 ± 7.99* [80.00 – 113.0] 95.68 ± 8.40* [77.00 – 112.0] 95.75 ± 9.22 [73.00 – 117.0] 95.55 ± 9.13 [74.00 – 115.0] 95.73 ± 9.09 [74.00 – 115.0]
Hip circumference (cm) 110.35 ± 9.30 [89.00 – 130.0] 109.2 ± 9.77* [88.00 – 128.0] 108.3 ± 9.96* [88.00 – 128.0] 108.59 ± 14.80 [48.00 – 138.0] 109.0 ± 13.91 [50.00 – 138.0] 108.3 ± 13.79 [50.00 – 137.0]
Waist circumference (cm) 102.80 ± 7.70 [84.00 – 118.0] 101.7 ± 7.69* [85.00 – 117.0] 100.5 ± 8.05* [82.00 – 115.0] 102.72 ± 10.14 [67.00 – 124.0] 102.2 ± 10.27 [68.00 – 124.0] 102.3 ± 10.12 [68.00 – 124.0]
Waist to hip ratio 0.93 ± 0.07 [0.80 - 0.95] 0.93 ± 0.07 [0.80 – 0.97] 0.92 ± 0.07 [0.79 – 0.96] 0.96 ± 0.12
[0.75 – 0.98]
0.94 ± 0.10 [0.74 – 0.98] 0.95 ± 0.10 [0.82 – 0.98]
  1. Values are expressed as Mean ± Standard deviation (SD). *p < 0.0001 as compared to baseline (Within group comparison). N = Number of patient in each treatment group